Compare DKI & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DKI | NVNO |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 6.8M |
| IPO Year | 2025 | 2017 |
| Metric | DKI | NVNO |
|---|---|---|
| Price | $2.51 | $9.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 32.1K | 26.1K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $31,243.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $140.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $0.30 |
| 52 Week High | $11.80 | $13.44 |
| Indicator | DKI | NVNO |
|---|---|---|
| Relative Strength Index (RSI) | 28.30 | 36.33 |
| Support Level | $0.34 | $8.84 |
| Resistance Level | $5.20 | $11.40 |
| Average True Range (ATR) | 0.27 | 0.73 |
| MACD | -0.06 | -0.20 |
| Stochastic Oscillator | 8.41 | 3.75 |
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.
enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.